AstraZeneca's antibody cocktail tests successfully

Monday, 11. October 2021 09:18

AstraZeneca announced on Monday that a trial of its AZD7443 long-acting antibody (LAAB) combination achieved positive results.

A statement from the company declared that the test "achieved a statistically significant reduction in severe COVID-19 or death compared to placebo in non-hospitalised patients with mild-to-moderate symptomatic COVID-19" and that "AZD7442 is the only long-acting antibody combination shown to both prevent and treat COVID-19."

Around 13% of participants were 65 years old or over and 90% were from high-risk populations overall.

Related Links: AstraZeneca plc
Baha Breaking News (BBN) / IB